These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

153 related articles for article (PubMed ID: 32700439)

  • 1. Long-term follow-up of children with risk organ-negative Langerhans cell histiocytosis after 2-chlorodeoxyadenosine treatment.
    Barkaoui MA; Queheille E; Aladjidi N; Plat G; Jeziorski E; Moshous D; Lambilliotte A; Kebaili K; Pacquement H; Leverger G; Mansuy L; Entz-Werlé N; Bodet D; Schneider P; Pagnier A; Lutun A; Gillibert-Yvert M; Millot F; Toutain F; Reguerre Y; Thomas C; Tazi A; Emile JF; Donadieu J; Héritier S
    Br J Haematol; 2020 Dec; 191(5):825-834. PubMed ID: 32700439
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Long-term efficacy and safety of 2CdA (cladribine) in extra-pulmonary adult-onset Langerhans cell histiocytosis: analysis of 23 cases from the French Histiocytosis Group and systematic literature review.
    Néel A; Artifoni M; Fontenoy AM; Tessoulin B; Lorillon G; Cohen-Aubart F; Haroche J; Genereau T; de Menthon M; Guillevin L; Maillard H; Kahn JE; Hermine O; Araujo C; Dromer C; Jullien D; Hamidou M; Donadieu J; Tazi A
    Br J Haematol; 2020 Jun; 189(5):869-878. PubMed ID: 32191819
    [TBL] [Abstract][Full Text] [Related]  

  • 3. [Results of treatment with 2-chlorodeoxyadenosine in refractory or relapsed Langerhans cell histiocytosis. Study of 9 patients].
    Grau J; Ribera JM; Tormo M; Indiano JM; Vercher J; Sandoval V; Ramírez G; Sastre A; Flores E; García-Conde J
    Med Clin (Barc); 2001 Mar; 116(9):339-42. PubMed ID: 11333766
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Egyptian experience in Langerhans cells histiocytosis: frequent multisystem affection and reactivation rates.
    Tantawy AAG; Ragab IA; Elsherif NHK; Makkeyah SM; AbdelRaheem HG; Elsantiel HIE
    Pediatr Hematol Oncol; 2020 Nov; 37(8):696-706. PubMed ID: 32706277
    [No Abstract]   [Full Text] [Related]  

  • 5. Treatment of children with Langerhans cell histiocytosis with 2-chlorodeoxyadenosine.
    Rodriguez-Galindo C; Kelly P; Jeng M; Presbury GG; Rieman M; Wang W
    Am J Hematol; 2002 Mar; 69(3):179-84. PubMed ID: 11891804
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Successful treatment of Langerhans cell histiocytosis with 2-chlorodeoxyadenosine.
    Goh NS; McDonald CE; MacGregor DP; Pretto JJ; Brodie GN
    Respirology; 2003 Mar; 8(1):91-4. PubMed ID: 12856748
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Vinblastine chemotherapy in adult patients with langerhans cell histiocytosis: a multicenter retrospective study.
    Tazi A; Lorillon G; Haroche J; Neel A; Dominique S; Aouba A; Bouaziz JD; de Margerie-Melon C; Bugnet E; Cottin V; Comont T; Lavigne C; Kahn JE; Donadieu J; Chevret S
    Orphanet J Rare Dis; 2017 May; 12(1):95. PubMed ID: 28532436
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Treatment of refractory Langerhans cell histiocytosis (LCH) with a combination of 2-chlorodeoxyadenosine and cytosine arabinoside.
    Apollonsky N; Lipton JM
    J Pediatr Hematol Oncol; 2009 Jan; 31(1):53-6. PubMed ID: 19125089
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Treatment of recurrent Langerhans cell histiocytosis in children with 2-chlorodeoxyadenosine.
    Mottl H; Starý J; Chánová M; Nekolná M; Drahokoupilová E; Smelhaus V
    Leuk Lymphoma; 2006 Sep; 47(9):1881-4. PubMed ID: 17065001
    [TBL] [Abstract][Full Text] [Related]  

  • 10. 2'-Chlorodeoxyadenosine (2-CdA) as salvage therapy for Langerhans cell histiocytosis (LCH). results of the LCH-S-98 protocol of the Histiocyte Society.
    Weitzman S; Braier J; Donadieu J; Egeler RM; Grois N; Ladisch S; Pötschger U; Webb D; Whitlock J; Arceci RJ
    Pediatr Blood Cancer; 2009 Dec; 53(7):1271-6. PubMed ID: 19731321
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Cladribine and cytarabine in refractory multisystem Langerhans cell histiocytosis: results of an international phase 2 study.
    Donadieu J; Bernard F; van Noesel M; Barkaoui M; Bardet O; Mura R; Arico M; Piguet C; Gandemer V; Armari Alla C; Clausen N; Jeziorski E; Lambilliote A; Weitzman S; Henter JI; Van Den Bos C;
    Blood; 2015 Sep; 126(12):1415-23. PubMed ID: 26194764
    [TBL] [Abstract][Full Text] [Related]  

  • 12. BRAF Mutation Correlates With High-Risk Langerhans Cell Histiocytosis and Increased Resistance to First-Line Therapy.
    Héritier S; Emile JF; Barkaoui MA; Thomas C; Fraitag S; Boudjemaa S; Renaud F; Moreau A; Peuchmaur M; Chassagne-Clément C; Dijoud F; Rigau V; Moshous D; Lambilliotte A; Mazingue F; Kebaili K; Miron J; Jeziorski E; Plat G; Aladjidi N; Ferster A; Pacquement H; Galambrun C; Brugières L; Leverger G; Mansuy L; Paillard C; Deville A; Armari-Alla C; Lutun A; Gillibert-Yvert M; Stephan JL; Cohen-Aubart F; Haroche J; Pellier I; Millot F; Lescoeur B; Gandemer V; Bodemer C; Lacave R; Hélias-Rodzewicz Z; Taly V; Geissmann F; Donadieu J
    J Clin Oncol; 2016 Sep; 34(25):3023-30. PubMed ID: 27382093
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Vemurafenib combined with cladribine and cytarabine results in durable remission of pediatric BRAF V600E-positive LCH.
    Evseev D; Osipova D; Kalinina I; Raykina E; Ignatova A; Lyudovskikh E; Baidildina D; Popov A; Zhogov V; Semchenkova A; Litvin E; Kotskaya N; Cherniak E; Voronin K; Burtsev E; Bronin G; Vlasova I; Purbueva B; Fink O; Pristanskova E; Dzhukaeva I; Erega E; Novichkova G; Maschan A; Maschan M
    Blood Adv; 2023 Sep; 7(18):5246-5257. PubMed ID: 37216396
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Langerhans cell histiocytosis: therapeutic strategy and outcome in a 30-year nationwide cohort of 1478 patients under 18 years of age.
    Rigaud C; Barkaoui MA; Thomas C; Bertrand Y; Lambilliotte A; Miron J; Aladjidi N; Plat G; Jeziorski E; Galambrun C; Mansuy L; Lutz P; Deville A; Armari-Alla C; Reguerre Y; Fraitag S; Coulomb A; Gandemer V; Leboulanger N; Moshous D; Hoang-Xuan K; Tazi A; Heritier S; Emile JF; Donadieu J
    Br J Haematol; 2016 Sep; 174(6):887-98. PubMed ID: 27273725
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Analysis of outcome for patients with mass lesions of the central nervous system due to Langerhans cell histiocytosis treated with 2-chlorodeoxyadenosine.
    Dhall G; Finlay JL; Dunkel IJ; Ettinger LJ; Kellie SJ; Allen JC; Egeler RM; Arceci RJ
    Pediatr Blood Cancer; 2008 Jan; 50(1):72-9. PubMed ID: 17455311
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Treatment of Langerhans cell histiocytosis with a modified risk-adapted protocol-experience from a tertiary cancer institute in India.
    Narula G; Pradhan ND; Arora B; Banavali SD
    Pediatr Blood Cancer; 2018 Aug; 65(8):e27028. PubMed ID: 29512864
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Nucleoside analogues in the therapy of Langerhans cell histiocytosis: a survey of members of the histiocyte society and review of the literature.
    Weitzman S; Wayne AS; Arceci R; Lipton JM; Whitlock JA
    Med Pediatr Oncol; 1999 Nov; 33(5):476-81. PubMed ID: 10531572
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Multisystem Langerhans cell histiocytosis in children: current treatment and future directions.
    Minkov M
    Paediatr Drugs; 2011 Apr; 13(2):75-86. PubMed ID: 21351807
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Exploration of treatment in childhood Langerhans cell histiocytosis based on inflammatory and malignant symptoms: a pilot study.
    Lin HL; Zheng QQ; Huang RL; Hu R; Liu XD; Wang JY
    Orphanet J Rare Dis; 2024 Apr; 19(1):174. PubMed ID: 38654381
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Treatment of multisystem Langerhans cell histiocytosis. Results of the DAL-HX 83 and DAL-HX 90 studies. DAL-HX Study Group.
    Minkov M; Grois N; Heitger A; Pötschger U; Westermeier T; Gadner H
    Klin Padiatr; 2000; 212(4):139-44. PubMed ID: 10994540
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.